107 related articles for article (PubMed ID: 9271838)
1. Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma.
Backe J; Gassel AM; Krebs S; Müller T; Caffier H
Arch Gynecol Obstet; 1997; 259(4):189-95. PubMed ID: 9271838
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G
Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702
[TBL] [Abstract][Full Text] [Related]
3. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
Coronado PJ; Vidart JA; Lopez-asenjo JA; Fasero M; Furio-bacete V; Magrina J; Escudero M
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):103-8. PubMed ID: 11516808
[TBL] [Abstract][Full Text] [Related]
4. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
Nazeer T; Ballouk F; Malfetano JH; Figge H; Ambros RA
Am J Obstet Gynecol; 1995 Dec; 173(6):1829-34. PubMed ID: 8610771
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
Hamel NW; Sebo TJ; Wilson TO; Keeney GL; Roche PC; Suman VJ; Hu TC; Podratz KC
Gynecol Oncol; 1996 Aug; 62(2):192-8. PubMed ID: 8751548
[TBL] [Abstract][Full Text] [Related]
6. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
7. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
8. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu amplification and overexpression in endometrial carcinoma.
Rolitsky CD; Theil KS; McGaughy VR; Copeland LJ; Niemann TH
Int J Gynecol Pathol; 1999 Apr; 18(2):138-43. PubMed ID: 10202671
[TBL] [Abstract][Full Text] [Related]
11. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Backe J; Gassel AM; Hauber K; Krebs S; Bartek J; Caffier H; Kreipe HH; Müller-Hermelink HK; Dietl J
Int J Gynecol Pathol; 1997 Oct; 16(4):361-8. PubMed ID: 9421076
[TBL] [Abstract][Full Text] [Related]
12. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
13. Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.
Gassel AM; Backe J; Krebs S; Schön S; Caffier H; Müller-Hermelink HK
J Clin Pathol; 1998 Jan; 51(1):25-9. PubMed ID: 9577367
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Pisani AL; Barbuto DA; Chen D; Ramos L; Lagasse LD; Karlan BY
Obstet Gynecol; 1995 May; 85(5 Pt 1):729-34. PubMed ID: 7724103
[TBL] [Abstract][Full Text] [Related]
15. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
17. Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium.
Rasty G; Murray R; Lu L; Kubilis P; Benrubi G; Masood S
Ann Clin Lab Sci; 1998; 28(3):138-43. PubMed ID: 9646853
[TBL] [Abstract][Full Text] [Related]
18. p53 protein overexpression in early stage endometrial cancer.
Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
Kalogiannidis I; Petousis S; Bobos M; Margioula-Siarkou C; Topalidou M; Papanikolaou A; Vergote I; Agorastos T
Arch Gynecol Obstet; 2014 Dec; 290(6):1231-7. PubMed ID: 25022554
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
